Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to trigger sufficient levels of insulin production in a phase 1/2 trial. The ...

Moreover, all 12 showed evidence that the islet cells had grafted and were ... developing a version called VX-264 in which the cells are encapsulated in a protective device designed to protect ...

In Part B of the study, participants received the full dose of the investigational fully differentiated pancreatic islet cell therapy encapsulated in a proprietary immunoprotective device.

Along with VX-880, it is also working on encapsulated islet cells as a treatment for T1D, although that programme remains in preclinical development. Encapsulation could mean doing away with the ...